CD30, Th2 cytokines and HIV infections: a complex and fascinating link
References (40)
- et al.
Cell
(1992) - et al.
Blood
(1985) - et al.
Blood
(1984) Immunol. Today
(1991)- et al.
Blood
(1991) - et al.
Immunol. Today
(1991) Curr. Opin. Immunol.
(1994)- et al.
Immunol. Today
(1991) - et al.
Clin. Immunol. Immunopathol.
(1993) - et al.
Immunol. Today
(1993)
Cell
Science
Science
J. Immunol.
J. Immunol.
Eur. J. Immunol.
Nature
J. Immunol.
Annu. Rev. Immunol.
Cited by (146)
TNF superfamily: Costimulation and clinical applications
2009, Cell Biology InternationalCitation Excerpt :As noted in the case of CD27, the soluble form of CD30 (∼85/88 kDa) is generated when membrane-bound CD30 protein is cleaved by zinc metalloproteinase (Hansen et al., 1995). Interestingly, soluble CD30 (sCD30) shedding can be found in several neoplastic and reactive diseases (Del Prete et al., 1995; Falini et al., 1995; Pizzolo et al., 1994, 1997; Romagnani et al., 1995) but the significance of sCD30 is not clear. In atopic dermatitis, CD30+ infiltrating T cells in lesions, elevated sCD30 levels, and increased number of circulating CD30+ cells were reported (Dummer et al., 2003).
HIV, 'An evolving species'. Roles of cellular activation and co-infections
2003, Medical HypothesesRegulation of lymphocyte clustering by CD30-mediated ICAM-1 up-regulation
2002, Cellular ImmunologyPrimary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review
2020, Current Hematologic Malignancy ReportsAssociation of high levels of plasma OX40 with acute adult T-cell leukemia
2019, International Journal of HematologyElevated levels of soluble CD26 and CD30 in multiple sclerosis
2015, Clinical and Experimental Neuroimmunology
We wish to thank: F. Almerigogna, F. Annunziato, R. Biagiotti, M. Chilosi, K. Daniel, M. De Carli, M.M. D'Elios, L Giannarini, M.G. Giudizi, R. Manetti, M. Mazzetti, L. Morosato, P. Parronchi, M-P. Piccinni, A. Ravina, S. Sampognaro, F. Vinante and G. Zancuoghi for their valuable collaboration. We also wish to thank D. Cosman and M. Alderson (Immunex, Seattle, Washington) for providing the M44 anti-CD30 and the M81 anti-CD30L mAbs, and H. Stein (Freie Universitat, Berlin, Germany) for helpful discussion. The experiments reported in this paper have been performed by grants provided by AIRC, Istituto Superiore di Sanità(AIDS Project), CNR (FATMA and ACRO Projects) and EU (Biotech Projects).
- 1
Gianfranco Del Prete, Enrico Maggi and Sergio Romagnani are at the Division of Clinical Immunology and Allergy, Universitty of Florence, 50134 Florence, Italy; Giovanni Pizzolo is at the Division of Hematology, University of Verona, 37134 Verona, Italy.